Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Scioto1on Jul 22, 2021 11:50am
191 Views
Post# 33587874

It must continue to press the same Management issues

It must continue to press the same Management issues
While the company continues to make progress with its clinical work, our management issues have not changed. I've raised this a few times since the board vote. Inevitably that leads to leads to folks rationalizing their board votes or criticizing others for theirs. Our work is not done. We must press management year round on the following issues: (1) we need to have board of members who play an active role in advising the company and expanding our reach. We should be pressing year round on building the board. (2) We need a board that invests in the company. It's patheticThe number of shares some board members own. Some startups actually pay their board members in stock. Not sure if it works in this situation but I like the idea. You get the point. (3) A plan and resources for engaging existing and potential shareholders. Shareholders. Here, I see some progress in trying to attract new shareholders. I'd be interested to hear from some of our larger shareholders about how they are engaging you and other institutional investors. SPCEO has created a weekly report card and I commend him for keeping that going. Not sure if there's agreement on my list or better ideas, but I think such items could easily parlay into regular measures so that we could determine progress and discuss how best to press management. These core issues will not not go away until they are made a priority by shareholders, board members, and management and worked on everyday while the folks in the labs do their job.
<< Previous
Bullboard Posts
Next >>